Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations


Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis

Final overall survival (OS) data from an open-label phase II trial revealed that, at a median follow-up of 28.4 months, savolitinib was associated with a median OS of 12.5 months (95% confidence intervals 10.5–21.4) in 70 Chinese patients with pre-treated (n=42) or treatment-naïve (n=28) pulmonary sarcomatoid carcinoma (PSC; n=25) or other non-small-cell lung cancers (NSCLCs) (n=45) harbouring MET exon14 skipping mutations (Abstract 2MO). The 18- and 24-month OS rates for all patients were 42% and 31%.

In subgroup analyses, the median OS times for pre-treated and treatment-naïve patients were 19.4 months and 10.9 months, respectively, with corresponding 18-month OS rates of 50% and 30%. Twelve PSC patients were pre-treated and 13 were treatment-naïve. The median OS times for PSC and other NSCLC patients were 10.6 months and 17.3 months, respectively, with corresponding 18-month OS rates of 30% and 49%. Among 15 patients with brain metastases, the median OS was 17.7 months the 18-month OS rate was 50%.

Abstract 2MO_ELCC 2022

Figure. Overall survival in patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon14 skipping mutations receiving savolitinib (European Lung Cancer Congress 2022, Abstract 2MO)

Grade ≥3 treatment-related adverse events were reported in 46% of patients, the most frequent being increases in aspartate aminotransferase (13%) and alanine aminotransferase (10%) along with peripheral oedema (9%). The incidence of adverse events was consistent across subgroups.

“We know that MET exon14 skipping mutations, which occur in 3–5% of patients with NSCLC, are driver mutations and that there is real clinical benefit in targeting them (Cancer Treat Rev. 2021;96:102179),” comments Dr Alfredo Addeo from Geneva University Hospital, Switzerland. “The activity of savolitinib in PSC, which has a poor prognosis, is encouraging and may help to define a group that could derive particular benefit from this treatment.” Also, this data support to perform molecular analysis on these cases to allow targeted treatments.

Although promising, however, Addeo cautions: “Data presented are not ground-breaking and are in line with what we have observed with the currently available MET tyrosine kinase inhibitors, tepotinib and capmatinib in MET exon14 skipping mutated NSCLC (N Engl J Med. 2020;383:931–943; N Engl J Med. 2020;383:944–957). We still urgently need new treatments that will help to raise the efficacy bar and provide more marked improvements in survival for what, in the case of PSC, is often a relatively young patient population.”

Abstract discussed:

Lu S, et al. Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC. European Lung Cancer Congress 2022, Abstract 2MO

Mini Oral Session 2, 30.03.2022, h. 14:15 - 15:15, Club A

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.